Philip Morris can market Zyn as less harmful tobacco product

[Stockholm, Sweden]
Alexander Farnsworth/iStock Editorial via Getty Images

Philip Morris (PM [https://seekingalpha.com/symbol/PM]) won regulatory backing to market its Zyn nicotine pouches with a modified risk claim that they pose a lower risk of tobacco-related disease than cigarettes—a significant victory for one of the company's fastest-growing brands.

“Today’s decision allows these products to be marketed with a modified risk claim that informs adults who smoke about the lower risks associated with these products,” the FDA said in Tuesday’s notification [https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-20-zyn-nicotine-pouches-be-marketed-specific-modified-risk-claim]on the agency’s website.

The Zyn nicotine pouches are made by Swedish Match, a wholly owned subsidiary of Philip Morris International (PM [https://seekingalpha.com/symbol/PM]).

The FDA allows 20 Zyn products to be marketed with a modified risk claim that puts the user at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.

In January 2025, the FDA allowed Swedish Match to sell Zyn products [https://www.pmi.com/investor-relations/press-releases-and-events/press-releases-overview/press-release-details?newsId=28291] but was not allowed to sell them as a safer alternative to cigarettes. With Tuesday’s decision, Swedish Match can sell the product as a safer alternative to tobacco products. Zyn contains nicotine but not tobacco, with the former responsible for addiction, but the latter more likely to cause severe health issues as the burning of tobacco releases tar and toxic chemicals.

“While a new tobacco product can be legally sold if the FDA authorizes it through the premarket tobacco product authorization pathway, seeking FDA authorization of the product through the MRTP pathway represents a meaningful harm reduction opportunity for manufacturers,” the FDA said.

The authorization is good for five years, before which Swedish Match may request and receive FDA authorization to continue marketing the product as a modified risk tobacco product (MRTP).

Philip Morris International (PM [https://seekingalpha.com/symbol/PM]) shares surrendered earlier gains and are now 0.85% in the red for the day, snapping a five-day winning streak.

MORE ON PHILIP MORRIS

* Philip Morris: King Of Tobacco In Consolidation Stage - Wait For A Dip [https://seekingalpha.com/article/4914538-philip-morris-king-of-tobacco-in-consolidation-stage-wait-for-a-dip]
* Philip Morris: IQOS And ZYN Offset Combustibles Volume Decline [https://seekingalpha.com/article/4913694-philip-morris-iqos-and-zyn-offset-combustibles-volume-decline]
* Philip Morris International Inc. (PM) Presents at 23rd annual dbAccess Global Consumer Conference Transcript [https://seekingalpha.com/article/4910908-philip-morris-international-inc-pm-presents-at-23rd-annual-dbaccess-global-consumer]
* Tobacco stocks edge higher as FDA proposes rule on foreign manufacturers [https://seekingalpha.com/news/4607729-tobacco-stocks-edge-higher-as-fda-proposes-rule-on-foreign-manufacturers]
* Dividend Roundup: Microsoft, Philip Morris, Coca-Cola, Target, and more [https://seekingalpha.com/news/4602911-dividend-roundup-microsoft-philip-morris-coca-cola-target-and-more]